IP Library › Granted Patent US 6,998,073
Granted Patent B2
US 6,998,073 · App. 10/321,951 · Granted Feb 14, 2006

Pulse extraction of ocular medical devices

Assignee: Bausch & Lomb Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,998,073
App. No.
10/321,951
Granted
Feb 14, 2006
Kind
B2
Abstract

A method of extracting residual materials from a polymeric, ophthalmic biomedical device, such as a contact lens, by using a mixture comprised of a primary solvent, such as carbon dioxide, and a polar co-solvent, such as isopropanol. By exposing the device to the co-solvent, the device expands. By pulsing or varying the concentration of the polar co-solvent in the mixture, the lens dimensions vary accordingly. When the lens is extracted while retained in a mold, the changes in lens dimensions causes the lens to be released from the mold.

Claims (21)

1. A method of extracting a polymeric, ophthalmic biomedical device contained within a chamber, said method comprising:

(a) subjecting said device to a supercritical fluid for a first predetermined time in said chamber;

(b) introducing isopropyl alcohol into said chamber to obtain a first mixture including a first predetermined level of isopropyl alcohol and subjecting said device to said first mixture for a second predetermined period of time;

(c) reducing the amount of isopropyl alcohol within said chamber to a second, lowered predetermined level and subjecting said device to the mixture for a third predetermined period of time; and

(d) subjecting said device to supercritical fluid for a fourth predetermined time such that said lens is in a dry slate,

wherein said device goes through at least one cycle of expansion and shrinkage.

2. The method of claim 1 , wherein said supercritical fluid is selected from the group consisting of supercritical carbon dioxide, supercritical nitrous oxide, supercritical methane, supercritical ethane, supercritical propane, supercritical butane, supercritical ethylene, supercritical fluoroform, and supercritical chloroform.

3. The method of claim 1 , wherein said first predetermined level contains at least 20% isopropyl alcohol and said second predetermined level contains 2 to 10% isopropyl alcohol.

4. The method of claim 1 , wherein said device is placed in a chamber and said extraction steps occur under pressures in the range of 69 to 276 bar and at temperatures in the range of 31° C. to 95° C.

5. The method of claim 1 , wherein the supercritical fluid is carbon dioxide.

6. The method of claim 1 , wherein steps (b) and (c) are repeated such that said device undergoes at least two cycles of expansion and shrinkage.

7. The method of claim 1 , wherein said device is a contact lens.

8. A method of extracting an ocular medical device comprising, sequentially:

(a) subjecting said device to a supercritical primary solvent, or a first mixture of a supercritical primary solvent and a co-solvent, in a chamber;

(b) subjecting said device to a second mixture of the supercritical primary solvent and a co-solvent in the chamber, wherein the concentration of the co-solvent is higher than the first mixture;

(e) reducing the level of the co-solvent in the chamber;

(d) repeating steps (a) through (c); and

(e) subjecting said device to the supercritical primary solvent to dry the device.

9. The process of claim 8 , wherein in step (c), substantially all of the co-solvent is removed from the chamber.

10. The process of claim 8 , wherein the device is a silicone hydrogel contact lens.

11. The process of claim 8 , wherein after step (c), substantially all of the primary solvent and co-solvent are removed front the chamber.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2012
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028726/0142 →
SECURITY AGREEMENT Recorded Mar 26, 2008
From: BAUSCH & LOMB INCORPORATED; WP PRISM INC.; B&L CRL INC.; B&L CRL PARTNERS L.P.; B & L DOMESTIC HOLDINGS CORP.; B&L FINANCIAL HOLDINGS CORP.; B&L SPAF INC.; B&L VPLEX HOLDINGS, INC.; BAUSCH & LOMB CHINA, INC.; BAUSCH & LOMB INTERNATIONAL INC.; BAUSCH & LOMB REALTY CORPORATION; BAUSCH & LOMB SOUTH ASIA, INC.; BAUSCH & LOMB TECHNOLOGY CORPORATION; IOLAB CORPORATION; RHC HOLDINGS, INC.; SIGHT SAVERS, INC.; WILMINGTON MANAGEMENT CORP.; WILMINGTON PARTNERS L.P.; B&L MINORITY DUTCH HOLDINGS LLC
To: CREDIT SUISSE
Reel/Frame 020733/0765 →
Continuity (3)
Division 0969841800 · Oct 27, 2000
Provisional Application 6017280600 · Dec 21, 1999
Related Publication 20030116873A1 · Jun 26, 2003